Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children

Available (expanded access)

Conditions studied: Peanut Allergy

In brief

This is an open label expanded access program for male and female patients 2 years or older, to provide continued desensitization treatment with DBV712 250 mcg.

Key facts

Study ID

NCT05424731

Run by

DBV Technologies

Last updated by the study team

2026-01-15

Who can join

Age: 2 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participation is by invitation, limited to individuals completing clinical study V712-303 (PEOPLE), previous Expanded Access Program or a DBV clinical study initiated after 31-Jan-2022
• Male and females; ages ≥ 2 years old at Visit 1 or current or prior studies.
• Negative urine pregnancy test for female participants of childbearing potential.

You may not qualify if…

• Early withdrawal from a DBV712 clinical study.
• History of non-compliance during the primary clinical study or unable to follow the protocol requirements.
• Generalized dermatologic disease extending widely on the skin.
• History of intolerance or who developed hypersensitivity to excipients of the DBV712 patches.

Where it is running

• Early Access Care, LLC — Madison, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.